Gsa Capital Partners LLP Blueprint Medicines Corp Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$85.18 - $108.78 $634,079 - $809,758	7,444 New	7,444 $802,000
Q3 2023 Nov 15, 2023	BUY	$46.9 - $66.0 $555,530 - $781,770	11,845 New	11,845 $594,000
Q4 2022 Feb 13, 2023	BUY	$41.06 - $66.48 $745,978 - $1.21 Million	18,168 New	18,168 $796,000
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $462,579 - $569,278	-4,908 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$80.98 - $109.47 $449,843 - $608,105	-5,555 Reduced 53.09%	4,908 $505,000
Q2 2021 Aug 05, 2021	BUY	$82.78 - $101.0 $866,127 - $1.06 Million	10,463 New	10,463 $920,000
Q1 2021 May 10, 2021	SELL	$90.71 - $108.28 $451,100 - $538,476	-4,973 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$92.08 - $124.48 $457,913 - $619,039	4,973 New	4,973 $558,000
Q4 2019 Feb 12, 2020	SELL	$66.73 - $82.59 $287,005 - $355,219	-4,301 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$72.9 - $101.41 $313,542 - $436,164	4,301 New	4,301 $316,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.